00738cam0 2200241 450 E60020001905620210426075728.020060616d1963 |||||ita|0103 baitaITGiocare al teatroMaria SignorelliRomaAmando1963119 p.ill.20 cmSignorelli, MariaAF00014588070482455ITUNISOB20210426RICAUNISOBUNISOB37015257E600200019056M 102 Monografia moderna SBNM370000579Si15257acquistopregresso2UNISOBUNISOB20060616115404.020190513094457.0SpinosaGiocare al teatro273302UNISOB04461nam 2201141z- 450 9910619465503321202210253-0365-5222-7(CKB)5670000000391619(oapen)https://directory.doabooks.org/handle/20.500.12854/93214(oapen)doab93214(EXLCZ)99567000000039161920202210d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNovel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of ActionMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (206 p.)3-0365-5221-9 Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue 'Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action', provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.Novel Anti-cancer Agents and Cellular Targets and Their MechanismHistory of engineering & technologybicsscTechnology: general issuesbicssc5-FU resistance8-hydroxydaidzeinaffibody drug conjugate (AffiDC)affibody moleculealbumin binding domainangiogenesisanti-cancer agentanticancer drugapoptosisAQ4NautophagyB-lactam steroid alkylatorsBCR-ABLbiomarkerbioprecursorbreast cancerBxPC-3c-myccancer hallmarksCCN1colorectal cancerConnectivity MapCYP1A1CYP1B1CYP2W1Cytochrome P450DM1drug repurposingduocarmycinEGFR tyrosine kinase inhibitoremtansineexpressiongene silencingGenomics of Drug Sensitivity in CancerglioblastomaHepG2Huh7human epidermal growth factor receptor 3 (HER3)hybrid steroidal alkylating agentsin vivo imaginginvasionisatin sulfonamidesK562MAPKmesenchymal-amoeboid transitionmicrotubule acetylationmigrationmolecular dockingn/ananoparticlesnanosystemsNF-κBoncogeneovarian cancerphortressphoton upconversionPLGApoly (ADP-ribose) polymerase inhibitorsprodrugRNA interferencesiRNAsynthetic lethalitytriple-negative breast cancertriplet-triplet annihilationHistory of engineering & technologyTechnology: general issuesAllison Simon Jedt1329056Allison Simon JothBOOK9910619465503321Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action3039279UNINA